TaiRx Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, dedicated to developing disease-modifying therapies for neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD)[1]. Founded in 2003, TaiRx has established itself as a leading CNS drug development company in Taiwan, leveraging proprietary small molecule platforms and advanced drug delivery technologies to address the growing burden of neurodegenerative diseases in aging populations[2].
| Attribute | Details |
|---|---|
| Headquarters | Taipei, Taiwan (Nankang Biotechnology Park) |
| Founded | 2003 |
| Focus Areas | Neurodegenerative diseases, CNS disorders, Alzheimer's disease, Parkinson's disease |
| Approach | Small molecule therapeutics, CNS drug delivery, protein aggregation inhibitors |
| Technology Platform | Blood-brain barrier (BBB) penetrating small molecules |
| Website | tairx.com.tw |
| Stock Symbol | Taiwan OTC |
TaiRx's proprietary platform focuses on developing small molecules specifically designed to cross the blood-brain barrier (BBB) and target key pathological mechanisms in neurodegenerative diseases[3]:
Key Platform Capabilities:
TaiRx has developed proprietary drug delivery technologies to enhance CNS drug delivery[4]:
TaiRx's PD program focuses on targeting multiple pathological pathways characteristic of Parkinson's disease[5]:
| Target | Mechanism | Development Stage |
|---|---|---|
| Alpha-synuclein aggregation | Inhibitor of α-syn oligomerization | Preclinical |
| Neuroinflammation | Microglial activation modulator | Research |
| Mitochondrial dysfunction | Complex I protector | Research |
The company's lead PD program targets alpha-synuclein (α-syn) aggregation, a hallmark pathological feature of Parkinson's disease and related synucleinopathies[6]:
TaiRx is developing therapies targeting neuroinflammation, a key contributor to PD progression[7]:
TaiRx's AD program includes amyloid-beta (Aβ) targeting therapies[8]:
The company is also developing therapies targeting tau pathology[9]:
| Program | Indication | Target | Stage |
|---|---|---|---|
| TaiRx-PD-001 | Parkinson's Disease | α-synuclein | Preclinical |
| TaiRx-PD-002 | Parkinson's Disease | Neuroinflammation | Research |
| TaiRx-AD-001 | Alzheimer's Disease | Amyloid-beta | Preclinical |
TaiRx maintains internal R&D facilities in Taiwan with capabilities in[10]:
The company utilizes various preclinical models for drug development:
TaiRx collaborates with leading Taiwanese research institutions[11]:
TaiRx has received support from Taiwan's Ministry of Economic Affairs and National Science and Technology Council.
TaiRx competes with global biotechnology companies developing PD therapeutics such as Prothena, Acumen, Neuraly, and Prevail[12].
The global PD market represents significant opportunity[13]:
Taiwan offers advantages for CNS drug development:
TaiRx's development strategy includes advancing lead compounds toward clinical candidates, planning Phase 1/2 trials for PD, and developing biomarker-based patient selection approaches[14].
TaiRx Inc. Company Website. 2026. ↩︎
Taiwan Biotechnology Industry Association. Taiwan Biotech Industry Overview. 2026. ↩︎
Pardridge WM. Blood-brain barrier drug delivery and target therapeutics. J Neurochem. 2014. ↩︎
Shoji J, et al. Development of CNS drug delivery platforms for neurodegenerative diseases. J Pharm Sci. 2021. ↩︎
Spillantini MG, et al. Alpha-synuclein in Lewy body disease. Nat Rev Neurol. 2017. ↩︎
Bridi JC, et al. Alpha-synuclein toxicity in neurodegeneration. Mol Neurobiol. 2023. ↩︎
Chen X, et al. Neuroinflammation in Parkinson's disease: therapeutic targets. Neuropharmacology. 2022. ↩︎
Karran E, et al. The amyloid cascade hypothesis of Alzheimer's disease. Nat Rev Neurosci. 2011. ↩︎
Ballard C, et al. Tau and Alzheimer's disease: an update. Nat Rev Neurol. 2021. ↩︎
Taiwan Ministry of Economic Affairs. Biotechnology Industry Development Plan. 2026. ↩︎
National Taiwan University. Neuroscience Research Programs. 2026. ↩︎
Prothena Corporation. Parkinson's Disease Pipeline. 2026. ↩︎
Dorsey ER, et al. Global, regional, and national burden of Parkinson's disease. Lancet Neurol. 2023. ↩︎
Ali M, et al. Drug development for neurodegenerative diseases: challenges and opportunities. Nat Rev Drug Discov. 2015. ↩︎